中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.011 seconds)

    IL-12/P40 BINDING PROTEINS
    2.
    发明申请
    IL-12/P40 BINDING PROTEINS 审中-公开
    IL-12 / P40结合蛋白

    公开(公告)号：WO2007005608A2

    公开(公告)日：2007-01-11

    申请号：PCT/US2006/025584

    申请日：2006-06-29

    Applicant: ABBOTT LABORATORIES ,  LACY, Susan E. ,  FUNG, Emma ,  BELK, Jonathan P. ,  DIXON, Richard W. ,  ROGUSKA, Michael ,  HINTON, Paul R. ,  KUMAR, Shankar

    Inventor： LACY, Susan E. ,  FUNG, Emma ,  BELK, Jonathan P. ,  DIXON, Richard W. ,  ROGUSKA, Michael ,  HINTON, Paul R. ,  KUMAR, Shankar

    IPC: C07K14/715

    CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

    Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

    ANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND USES THEREOF
    7.
    发明申请
    ANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND USES THEREOF 审中-公开
    抗精神病药物受体的抗体及其用途

    公开(公告)号：WO2009029123A1

    公开(公告)日：2009-03-05

    申请号：PCT/US2007/087514

    申请日：2007-12-14

    Applicant: ABBOTT LABORATORIES ,  REILLY, Edward, B. ,  LACY, Susan, E. ,  FUNG, Emma ,  BELK, Jonathan, P. ,  ROGUSKA, Michael ,  STOLL, Vincent, S. ,  JAKOB, Clarissa

    Inventor： REILLY, Edward, B. ,  LACY, Susan, E. ,  FUNG, Emma ,  BELK, Jonathan, P. ,  ROGUSKA, Michael ,  STOLL, Vincent, S. ,  JAKOB, Clarissa

    IPC: C07K16/28

    CPC classification number: C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2317/92

    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions. The invention further provides compositions and crystals of an erythropoietin receptor in complex with an anti-erythropoietin receptor antibody. Specifically, the high-resolution structure provides binding sites defined by the structure coordinated determined herein.

    Abstract translation: 本发明涉及结合并激活促红细胞生成素受体的抗体及其抗原结合部分。 本发明还涉及编码这种抗体和抗原结合部分的核酸序列。 本发明还涉及使用所述抗体和抗原结合部分，治疗方法以及包含所述抗体和抗原结合部分的药物组合物来激活哺乳动物中促红细胞生成素受体的内源性活性的方法。 本发明还提供与抗促红细胞生成素受体抗体复合的促红细胞生成素受体的组合物和晶体。 具体地，高分辨率结构提供由本文确定的结构所定义的结合位点。

    IL-12/P40 BINDING PROTEINS
    9.
    发明申请
    IL-12/P40 BINDING PROTEINS 审中-公开
    IL-12 / P40结合蛋白

    公开(公告)号：WO2007005608A3

    公开(公告)日：2008-10-09

    申请号：PCT/US2006025584

    申请日：2006-06-29

    Applicant: ABBOTT LAB ,  LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

    Inventor： LACY SUSAN E ,  FUNG EMMA ,  BELK JONATHAN P ,  DIXON RICHARD W ,  ROGUSKA MICHAEL ,  HINTON PAUL R ,  KUMAR SHANKAR

    IPC: C07K16/00

    CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

    Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

Patent Agency Ranking